ORBIMED ADVISORS LLC 13D and 13G filings for Edgewise Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 5:23 pm Unchanged | 2024-11-07 | 13D | Edgewise Therapeutics, Inc. EWTX | ORBIMED ADVISORS LLC | 14,756,096 15.600% | 0 (Unchanged) | Filing |
| 2024-01-25 4:25 pm Purchase | 2024-01-23 | 13D | Edgewise Therapeutics, Inc. EWTX | ORBIMED ADVISORS LLC | 14,756,096 17.300% | 454,545 (+3.18%) | Filing |
| 2022-09-16 4:23 pm Purchase | 2022-09-16 | 13D | Edgewise Therapeutics, Inc. EWTX | ORBIMED ADVISORS LLC | 14,301,551 23.300% | 622,496 (+4.55%) | Filing |
| 2021-04-07 6:00 pm Purchase | 2021-03-30 | 13D | Edgewise Therapeutics, Inc. EWTX | ORBIMED ADVISORS LLC | 13,679,055 27.800% | 13,679,055 (New Position) | Filing |